Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is ...

The double-blind, placebo-controlled Phase II trial is enrolling approximately 100 adult participants with tardive dyskinesia ...

Accurate and early diagnosis of tardive dyskinesia (TD), a serious movement disorder typically caused by exposure to antipsychotic medications, is imperative for long-term management. "Keeping an eye ...

Tardive dyskinesia shares features with other movement disorders, such as Tourette syndrome and drug-induced Parkinsonism. But a diagnostic evaluation can reveal which condition is causing the ...

Tardive dyskinesia causes involuntary movements in some people taking antipsychotic medications. Here’s what you need to know about this movement disorder. Antipsychotic medications are a mainstay of ...

Tardive dyskinesia is not typically reversible, but on rare occasions, it can be if caught early and treated immediately. Tardive dyskinesia (TD) is a medication-induced movement disorder involving ...

So one of the trials that I'm interested in watching is an extension trial of the IMPACT-TD registry that's currently going on and being done by Teva Pharmaceuticals, who are the manufacturers of ...

Patients on antipsychotics need to be regularly monitored for signs of tardive dyskinesia, a medication-induced movement disorder diagnosed when the involuntary movements persist for at least a month ...

Kristin Weiland is a documentary film producer and writer with a background in crisis management and ethnographic research. She specializes in investigative and social impact documentary projects, and ...

TUESDAY, Aug. 22, 2023 (HealthDay News) -- Tardive dyskinesia (TD) has a considerable impact on physical, psychological, social, and professional lives, according to a study published in the May/June ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients with tardive dyskinesia were adherent to deutetrabenazine vs. valbenazine.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational ...